Vimarsana
Biggest News Aggregation in the World

Amyk Mottl News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Amyk Mottl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Amyk Mottl Today - Breaking & Trending Today

Diabetic Glomerulosclerosis Severity Tied to Outcomes in Glomerular Disease - Vimarsana News

Diabetic Glomerulosclerosis Severity Tied to Outcomes in Glomerular Disease

Patients with moderate to severe diabetic glomerulosclerosis on top of primary glomerular disease may have greater risks for kidney failure and death. Investigators performed a detailed analysis of real-world patients with glomerular disease and diabetic glomerulosclerosis and outcomes.

Diabetic Glomerulosclerosis Severity Tied to Outcomes in Glomerular Disease - Vimarsana News

Diabetic Glomerulosclerosis Severity Tied to Outcomes in Glomerular Disease

Patients with moderate to severe diabetic glomerulosclerosis on top of primary glomerular disease may have greater risks for kidney failure and death. Investigators performed a detailed analysis of real-world patients with glomerular disease and diabetic glomerulosclerosis and outcomes.

Experts Elevate New Drugs for Diabetic Kidney Disease - Vimarsana News

Experts Elevate New Drugs for Diabetic Kidney Disease

A consensus statement from the ADA and KDIGO recommends more aggressive combined use of several newer, and costly, drug classes to slow progression of diabetic kidney disease.

AKI Risk in COVID-19 vs Flu Not Disproportionately Higher With RAASi Use - Vimarsana News

AKI Risk in COVID-19 vs Flu Not Disproportionately Higher With RAASi Use

RAAS inhibitor use is not associated with a disproportionately higher risk for acute kidney injury in patients with COVID-19.

Source: empr.com
AKI Risk in COVID-19 vs Flu Not Disproportionately Higher With RAASi Use - Vimarsana News

AKI Risk in COVID-19 vs Flu Not Disproportionately Higher With RAASi Use

RAAS inhibitor use is not associated with a disproportionately higher risk for acute kidney injury in patients with COVID-19.